Prognosis of Early-Stage HFpEF in the Community-Dwelling Elderly: The Northern Shanghai Study
Authors:
Open Access
- 12 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (1) , 229-238
Abstract
Objective: Heart failure with preserved ejection fraction (HFpEF) is a growing concern among the elderly population, significantly impacting morbidity and mortality rates. This study aimed to screen and investigate the characteristics and prognosis of early-stage HFpEF in the elderly. Methods: A total of 1789 community-dwelling individuals aged over 65 from northern Shanghai were enrolled. According to American Heart Association (AHA) guidelines, participants were classified into four groups: HFpEF stage 0, HFpEF stage A, HFpEF stage B and HFpEF stage C. Major endpoints included major adverse cardiovascular events (MACEs), all-cause death and cardiovascular death. Results: After a mean follow-up period of 7.10 ± 1.27 years, 1623 elderly subjects were included [HFpEF stage 0 (10.3%), HFpEF stage A (16.3%), HFpEF stage B (60.6%) and HFpEF stage C (12.8%)]. Patients with HFpEF stage A, HFpEF stage B and HFpEF stage C exhibited more MACEs than those in HFpEF stage 0 (P < 0.01). Patients with HFpEF stage C had a significantly higher cardiovascular (P < 0.001) and all-cause death ratio (P < 0.01). With HFpEF stage 0 as a reference, the increases in MACEs were significantly associated with HFpEF stage A [hazard ratio (HR): 2.97, 95% confidence interval (CI) (1.13, 7.82), P < 0.05], HFpEF stage B [HR: 2.69, 95% CI (1.09, 6.64), P < 0.05] and HFpEF stage C [HR: 4.86, 95% CI (1.88, 12.59), P < 0.01] in the Cox regression analysis. Our finding remains unaltered in the sensitivity analysis, with no interaction for effectiveness. Conclusions: Compared with those with HFpEF stage 0, patients with HFpEF, whether in stage B or C, exhibit significantly higher cardiovascular and all-cause mortality in the elderly. This study underscores the importance of early-stage HFpEF screening, particularly in older, asymptomatic stage B individuals.Keywords
Funding Information
- National Nature Science Foundation of China (82170388)
- National Nature Science Foundation of China (82370300)
- Shanghai Technology Research Leader Program (21XD1434700)
- Cardiac rehabilitation fund by the International Medical Exchange Foundation (Z-2019-42-1908-3)
- Grant for the construction of Innovative Flagship Hospital for Integrated Traditional Chinese and Western Medicine (ZY(2021-2023)-0205-05)
- National Natural Science Foundation of China (82170388)
- National Natural Science Foundation of China (82370300)
- Program of Shanghai Academic Research Leader (21XD1434700)
This publication has 28 references indexed in Scilit:
- Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2023
- Heart Failure With Preserved Ejection FractionJAMA, 2023
- Prevalence and Prognosis of Frailty in Older Patients with Stage B Heart Failure with Preserved Ejection FractionESC Heart Failure, 2023
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureEuropean Journal of Heart Failure, 2021
- Epidemiology of Heart FailureEuropean Journal of Heart Failure, 2020
- Hypertension and Heart FailureHeart Failure Clinics, 2020
- Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2018
- Heart Failure With Preserved, Borderline, and Reduced Ejection FractionJACC, 2017
- Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2017
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005